EGFR and colorectal neoplasm: In conclusion, our results demonstrate that SRC has a dominant role in mediating the unresponsiveness of BRAFV600E colorectal tumors to BRAF inhibitors and suggest that SRC and EGFR act in conserved, complementary, parallel circuits that drive resistance and can be jointly targeted to restore therapeutic sensitivity.